| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.17 | 0.0004 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.087 | 0.05 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.088 | 0.07 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.077 | 0.09 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.091 | 0.09 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.08 | 0.1 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.07 | 0.1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.07 | 0.2 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.071 | 0.2 |